Ikarian Capital, LLC recently filed their 13F report for the first quarter of 2022, which ended on 2022-03-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
100 CRESCENT COURT DALLAS, TX 75201
As of the latest 13F report, the guru’s equity portfolio contained 196 stocks valued at a total of $760,000,000. The top holdings were BCYC(2.76%), CLDX(2.41%), and KZR(2.37%).
According to GuruFocus data, these were Ikarian Capital, LLC’s top five trades of the quarter.
Bicycle Therapeutics PLC
Ikarian Capital, LLC reduced their investment in NAS:BCYC by 134,342 shares. The trade had a 1.22% impact on the equity portfolio. During the quarter, the stock traded for an average price of $46.72.
On 05/16/2022, Bicycle Therapeutics PLC traded for a price of $17.37 per share and a market cap of $506,989,000. The stock has returned -41.68% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Bicycle Therapeutics PLC has a price-book ratio of 1.53, a EV-to-Ebitda ratio of -1.93 and a price-sales ratio of 33.73.
The price-to-GF Value ratio is 0.87, earning the stock a GF Value rank of 3.
Sierra Oncology Inc
Ikarian Capital, LLC reduced their investment in NAS:SRRA by 351,114 shares. The trade had a 1.14% impact on the equity portfolio. During the quarter, the stock traded for an average price of $28.62.
On 05/16/2022, Sierra Oncology Inc traded for a price of $54.595 per share and a market cap of $1,332,809,000. The stock has returned 210.99% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Sierra Oncology Inc has a price-book ratio of 4.97 and a EV-to-Ebitda ratio of -10.40.
Sage Therapeutics Inc
The guru established a new position worth 249,907 shares in NAS:SAGE, giving the stock a 1.09% weight in the equity portfolio. Shares traded for an average price of $37.62 during the quarter.
On 05/16/2022, Sage Therapeutics Inc traded for a price of $32.59 per share and a market cap of $1,896,615,000. The stock has returned -55.78% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Sage Therapeutics Inc has a price-book ratio of 1.18, a EV-to-Ebitda ratio of -0.59 and a price-sales ratio of 300.10.
The price-to-GF Value ratio is 1.14, earning the stock a GF Value rank of 4.
Biogen Inc
Ikarian Capital, LLC reduced their investment in NAS:BIIB by 28,411 shares. The trade had a 1.02% impact on the equity portfolio. During the quarter, the stock traded for an average price of $217.68.
On 05/16/2022, Biogen Inc traded for a price of $199.02 per share and a market cap of $29,014,341,000. The stock has returned -29.32% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Biogen Inc has a price-earnings ratio of 20.28, a price-book ratio of 2.59, a EV-to-Ebitda ratio of 11.35 and a price-sales ratio of 2.72.
The price-to-GF Value ratio is 0.82, earning the stock a GF Value rank of 10.
Biohaven Pharmaceutical Holding Co Ltd
The guru established a new position worth 60,000 shares in NYSE:BHVN, giving the stock a 0.94% weight in the equity portfolio. Shares traded for an average price of $124.91 during the quarter.
On 05/16/2022, Biohaven Pharmaceutical Holding Co Ltd traded for a price of $140.92 per share and a market cap of $10,013,537,000. The stock has returned 113.47% over the past year.
GuruFocus gives the company a financial strength rating of 2 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Biohaven Pharmaceutical Holding Co Ltd has a EV-to-Ebitda ratio of -19.82 and a price-sales ratio of 12.91.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
